个人简介

彭亮,副研究员(已获卫健委研究员资格),中日友好医院科技中心(科研处)副主任/基础研究部主任,北京协和医学院、北京大学医学部、首都医科大学及中日友好临床医学研究所硕士生导师。

2009年博士毕业于中国医学科学院&北京协和医学院肿瘤研究所分子肿瘤学国家重点实验室,毕业后在中日友好医院临床医学研究所工作至今。期间2015年9月至2016年12月在美国耶鲁大学医学院GeraldI.Shulman院士实验室作访问学者。主要研究方向为肥胖、非酒精性脂肪肝、糖尿病等代谢性疾病的发病机制研究。以通讯或第一作者在SCI杂志CellMetabolism、Metabolism、PharmacologicalResearch、InternationalJournalofBiologicalSciences、Phytomedicine、JBC、FASEBJournal、MolecularNutrition&FoodResearch、JournalofNutritionalBiochemistry、LifeScience、Carcinogenesis、JournalofEndocrinology及Cellulose等发表论著35篇(累计IF=247,单篇最高IF=20.6,单篇最高引用226次),主持“国家自然科学基金”4项、“北京自然科学基金”3项、“首都卫生发展科研专项”1项、“中国医学科学院青年医学人才奖励项目”1项、“北京市研究型病房建设临床研究项目”1项、“北京化工大学-中日友好医院生物医学转化工程研究中心联合项目”1项、“中日友好医院高水平医院临床业务费专项”1项以及“中日医院青年科技英才课题”1项,此外参与6项国家级课题。

研究方向:

主要研究方向为肥胖、非酒精性脂肪肝、糖尿病等代谢性疾病的发病机制和药物防治研究

合作或招生需求:

1.常年招收基础医学、病理生理学、中西医结合基础、药理学等专业联合培养研究生。

2.研究生需对科研有较强的兴趣、勤奋努力、良好的沟通能力。

联系方式:pengliang8028@163.com

近年代表性学术论文(第一或通讯作者):

1.PerryRJ#,PengL#,ClineGW,PetersenKF,ShulmanGI:ANon-invasiveMethodtoAssessHepaticAcetyl-CoAInVivo.CellMetab2017,25(3):749-756.

2.WangS,WangY,LinL,LiZ,LiuF,ZhuL,ChenJ,ZhangN,CaoX,RanS,LiuG,GaoP,SunW,PengL*,ZhuangJ*,MengH*:Layer-SpecificBTX-ADeliverytotheGastricMuscularisAchievesEffectiveWeightControlandMetabolicImprovement.AdvSci(Weinh).2023Oct;10(28):e2300822

3.ZhangH,LuJ,LiuH,GuanL,XuS,WangZ,QiuY,LiuH,PengL*,MenX#*:AjugolenhancesTFEB-mediatedlysosomebiogenesisandlipophagytoalleviatenon-alcoholicfattyliverdisease.PharmacolRes2021,174:105964.

4.LiuT,LiQ,JinQ,YangL,MaoH,QuP,GuoJ,ZhangB,MaF,WangY,PengL*,LiP*,ZhanY*.TargetingHMGB1:APotentialTherapeuticStrategyforChronicKidneyDisease.IntJBiolSci.2023Sep25;19(15):5020-5035

5.ZhaiY,ZhouW,YanX,QiaoY,GuanL,ZhangZ,LiuH,JiangJ,LiuJ*,PengL*.AstragalosideIVamelioratesdiet-inducedhepaticsteatosisinobesemicebyinhibitingintestinalFXRviaintestinalfloraremodeling.Phytomedicine.2022Dec;107:154444.

6.ZhouW,YanX,ZhaiY,LiuH,GuanL,QiaoY,JiangJ*,PengL*.PhillygeninamelioratesnonalcoholicfattyliverdiseaseviaTFEB-mediatedlysosomebiogenesisandlipophagy.Phytomedicine.2022Aug;103:154235.

7.ZhangZ,QiaoY,SunQ,PengL*,SunL*.AnovelSLC25A1inhibitor,parthenolide,suppressesthegrowthandstemnessoflivercancerstemcellswithmetabolicvulnerability.CellDeathDiscov.2023Sep23;9(1):350.

8.YanX,ZhaiY,ZhouW,QiaoY,GuanL,LiuH,JiangJ*,PengL*.IntestinalFloraMediatesAntiobesityEffectofRutininHigh-Fat-DietMice.MolNutrFoodRes.2022Jul;66(14):e2100948.

9.LiuH,GuoL,ZhangH,ZhouWL,GuanLL,YanX,ZhaiYY,QiaoY,WangZ,WangHT*,PengL*.Quercetinprotectsagainstpalmitate-inducedpancreaticβ-cellapoptosisbyrestoringlysosomalfunctionandautophagicflux.JNutrBiochem.2021,35:652-659.

10.WangY,LiuH,ZhangR,XiangY,LuJ,XiaB*,PengL*,WuJ*.AdipoRonexertsopposingeffectsoninsulinsensitivityviafibroblastgrowthfactor21-mediatedtime-dependentmechanisms.JBiolChem.2022Mar;298(3):101641.

11.LiZ,LiuD,GuR,QiaoY,JinQ,ZhangY,RanS,LiuX,WangY,MaoN,QinY,PengL*,WangJ*.Fecalmicrobiotatransplantationinobesitymetabolism:Ametaanalysisandsystematicreview.DiabetesResClinPract.2023Aug:202:110803.

12.JinQ,LiuT,QiaoY,LiuD,YangL,MaoH,MaF,WangY,PengL*,ZhanY*.Oxidativestressandinflammationindiabeticnephropathy:roleofpolyphenols.FrontImmunol.2023;14:1185317.

13.JinQ,LiuT,MaF,YangL,MaoH,WangY,LiP,PengL*,ZhanY*.TherapeuticapplicationoftraditionalChinesemedicineinkidneydisease:Sirtuinsaspotentialtargets.BiomedPharmacother.2023Sep22:167:115499

14.QiaoY,GuanLL,ZhaiYY,YanX,ZhouWL,LiuH,ZhangZC,andPengL*Apigeninalleviatesobesity-associatedmetabolicsyndromebyregulatingthecompositionofthegutmicrobiome.FrontMicrobiol.2021:11:52-59.

15.WangZ,LuJ,ZhouJ,SunW,QiuY,ChenW,GaoY,YangR,AiS,LiuZ,WangYandPengL*:ModulationoftheGutMicrobiotabyShen-Yan-Fang-ShuaiFormulaImprovesObesityInducedbyHigh-FatDiets.FrontMicrobiol2020,11:564376.

16.LuJF,ZhuMQ,ZhangH,LiuH,XiaB,WangYL,ShiX,PengL*,WuJW*:Neohesperidinattenuatesobesitybyalteringthecompositionofthegutmicrobiotainhigh-fatdiet-fedmice.FASEBJ2020,34(9):12053-12071.

17.XuS,LiJ,ZhaiM,YaoX,LiuH,DengT,CaiH,ZhangW,ZhangW,LouJ,PengL*:1,25-(OH)2D3protectsSchwanncellsagainstadvancedglycationendproducts-inducedapoptosisthroughPKA-NF-kappaBpathway.LifeSci2019,225:107-116.

18.WangY,ZhaoH,LiX,WangQ,YanM,ZhangH,ZhaoT,ZhangN,ZhangP,PengL*,LiP*:FormononetinalleviateshepaticsteatosisbyfacilitatingTFEB-mediatedlysosomebiogenesisandlipophagy.JNutrBiochem2019,73:108214.

19.GuoL,LiuP,GaoL,WangZ,HuangS,PengL*,ZhaoZ.Chrtosanhydrogel,asabiologicalmacromolecule-baseddrugdeliverysystemforexosomesandmicrovesiclesinregenerativemedicine:aminireview.Cellulose.2021Nov06

20.WangY,ZhaoH,LiX,LiN,WangQ,LiuY,LiangQ,ShaoZ,ZhangN,ZhaoT,PengL*,LiP*:TangshenFormulaAlleviatesHepaticSteatosisbyInducingAutophagyThroughtheAMPK/SIRT1Pathway.FrontPhysiol2019,10:494.

21.GaoY,YangR,GuoL,WangY,LiuWJ,AiS,WoonTH,WangZ,ZhaiY,WangZ*,PengL*:Qing-Re-Xiao-ZhengFormulaModulatesGutMicrobiotaandInhibitsInflammationinMiceWithDiabeticKidneyDisease.FrontMed(Lausanne)2021,8:719950.

22.XuS,BaoW,MenX,LiuY,SunJ,LiJ,LiuH,CaiH,ZhangW,LouJ,PengL*:Interleukin-10ProtectsSchwannCellsagainstAdvancedGlycationEndProducts-InducedApoptosisviaNF-kappaBSuppression.ExpClinEndocrinolDiabetes2020,128(2):89-96.

23.SongD,ChenY,WangX,ChenX,GaoS,XuW,YangS,WangZ,PengL*,DaiH*.AMouseModelofPulmonaryFibrosisInducedbyNasalBleomycinNebulization.JVisExp.2023Jan20:(191).doi:10.3791/64097.